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Abstract: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in 
women. The clinical manifestation of PCOS varies from a mild menstrual disorder to severe 
disturbance of reproductive and metabolic functions. Management of women with PCOS depends 
on the symptoms. These could be ovulatory dysfunction-related infertility, menstrual disorders, 
or androgen-related symptoms. Weight loss improves the endocrine profile and increases the 
likelihood of ovulation and pregnancy. Normalization of menstrual cycles and ovulation could 
occur with modest weight loss as little as 5% of the initial weight. The treatment of obesity 
includes modifications in lifestyle (diet and exercise) and medical and surgical treatment. 
In PCOS, anovulation relates to low follicle-stimulating hormone concentrations and the arrest 
of antral follicle growth in the final stages of maturation. This can be treated with medications 
such as clomiphene citrate, tamoxifen, aromatase inhibitors, metformin, glucocorticoids, or 
gonadotropins or surgically by laparoscopic ovarian drilling. In vitro fertilization will remain 
the last option to achieve pregnancy when others fail. Chronic anovulation over a long period of 
time is also associated with an increased risk of endometrial hyperplasia and carcinoma, which 
should be seriously investigated and treated. There are androgenic symptoms that will vary from 
patient to patient, such as hirsutism, acne, and/or alopecia. These are troublesome presentations 
to the patients and require adequate treatment. Alternative medicine has been emerging as one of 
the commonly practiced medicines for different health problems, including PCOS. This review 
underlines the contribution to the treatment of different symptoms.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in 
women. Its prevalence among infertile women is 15%–20%. The etiology of PCOS 
remains unclear; however, several studies have suggested that PCOS is an X-linked 
dominant condition. Women with PCOS have abnormalities in the metabolism of 
androgens and estrogen and in the control of androgen production. High serum 
concentrations of androgenic hormones, such as testosterone, androstenedione, and 
dehydroepiandrosterone sulfate (DHEAS), may be encountered in these patients. 
However, individual variation is considerable, and a particular patient might have 
normal androgen levels. PCOS is also associated with peripheral insulin resistance 
and hyperinsulinemia, and obesity amplifies the degree of both abnormalities. Insulin 
resistance in PCOS can be secondary to a postbinding defect in insulin receptor 
signaling pathways, and elevated insulin levels may have gonadotropin-augmenting 
effects on ovarian function. In addition, insulin resistance in PCOS has been associated International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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with   adiponectin, a hormone secreted by adipocytes that 
regulates lipid metabolism and glucose levels. Both lean 
and obese women with PCOS have lower adiponectin levels 
than women without PCOS. A proposed mechanism for 
anovulation and elevated androgen levels suggests that under 
the increased stimulatory effect of luteinizing hormone (LH) 
secreted by the anterior pituitary, stimulation of the ovarian 
theca cells is increased. In turn, these cells increase the 
production of androgens (eg, testosterone, androstenedione). 
Because of a decreased level of follicle-stimulating hormone 
(FSH) relative to LH, the ovarian granulosa cells cannot 
aromatize the androgens to estrogens, which leads to 
decreased estrogen levels and consequent anovulation. 
Growth hormone and insulin-like growth factor 1 may also 
augment the effect on ovarian function.1,2
In this review, the state of the art in the treatment of differ-
ent aspects of PCOS, from anovulation to hyperandrogenism, 
is discussed, with a particular emphasis on the emerging new 
modalities of treatment such as alternative therapy.
Diagnosis of PCOS
The clinical manifestation of PCOS varies from a mild menstrual 
disorder to severe disturbance of reproductive and metabolic 
functions. Women with PCOS are predisposed to type 2 dia-
betes or develop cardiovascular disease.3 Factors implicated in 
the low fertility in these patients include anovulation, increased 
risk of early miscarriage, and late obstetric complications. 
Clinical manifestations include menstrual disorders and signs 
of hyperandrogenism. Although not universal and not part of 
the definition, insulin resistance and obesity are also extremely 
common accompaniments of this   syndrome.4 This phenotypic 
nonuniformity and the variability of   presentation have made it 
difficult to define the syndrome.
The 1990 National Institutes of Health (NIH)-sponsored 
conference for definition required oligo-ovulation, clinical 
or biochemical hyperandrogenism, and the exclusion of 
other known disorders, such as late-onset congenital adrenal 
  hyperplasia and Cushing’s syndrome5 (Table 1). The   diagnostic 
criteria of the syndrome were revised by the Rotterdam 
European Society for Human Reproduction/American 
Society of Reproductive Medicine (ASRM)-sponsored PCOS 
consensus workshop group in 2003, where the following 
criteria were established: oligo/amenorrhea, clinical and 
biochemical signs of hyperandrogenism, and sonographically 
confirmed PCOS.6 Two of the three criteria are required 
for diagnosis (after exclusion of other etiologies such as 
congenital adrenal hyperplasia, androgen-secreting tumors, 
or Cushing’s syndrome). Sonographic features of PCOS 
include the presence of 12 or more follicles in each ovary 
measuring 2–9 mm in diameter and/or increased ovarian 
volume (.10 mL). This is regardless of follicle distribution 
or ovarian stromal echogenicity. One ovary fulfilling this 
definition is sufficient to define PCOS.2,7 It is recognized 
that some women with sonographic findings of PCOS may 
have regular cycles without clinical or biochemical signs 
of hyperandrogenism. Although this has been a practical 
working definition, others believe that hyperandrogenism 
should be an integral part of the definition.
Ovulatory women with PCOS seem to be less insulin 
resistant than anovulatory women with PCOS;8 further, 
a study published in 2007 suggests that women with PCOS,9 
chronic anovulation, and normal androgen levels are not 
insulin resistant. These observations limit the usefulness 
of the Rotterdam criteria, and accordingly an expert panel 
of the Androgen Excess Society (AES) recommended that 
PCOS should be considered a disorder of androgen excess 
and that the NIH diagnostic criteria should be used.7 The 
AES also recommended that women with hyperandrogenism, 
PCOS, and ovulatory cycles should be considered to have 
a PCOS phenotype; thus, hyperandrogenism and infrequent 
or irregular ovulation, as well as hyperandrogenism, regular 
ovulation, and PCOS, fulfill AES criteria for PCOS.
Management of PCOS
Management of women with PCOS depends on the   symptoms. 
These could be ovulatory dysfunction-related infertility, 
  menstrual disorders, or androgen-related symptoms.
Weight reduction
There is some evidence that PCOS-related hyperandrogenism 
causes central obesity with a high waist/hip ratio independent 
Table 1 Diagnostic criteria
Organization/group Year Criteria
National Institutes  
of Health
1990 Both hyperandrogenism and  
chronic anovulation5
Rotterdam European  
Society for Human  
Reproduction/American 
Society of Reproductive  
Medicine-sponsored  
PCOS consensus 
workshop group
2003 Two of the following conditions:  
hyperandrogenism, chronic 
anovulation, polycystic ovary6
Androgen Excess  
Society
2006 Hyperandrogenism and ovarian  
dysfunction (including infrequent 
or irregular ovulation or anovulation)   
and/or polycystic ovary7
Abbreviation: PCOS, polycystic ovary syndrome.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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of the body mass index (BMI). It is well established that 
obesity is associated with anovulation, miscarriage, or 
late pregnancy complications (such as pre-eclampsia and 
gestational diabetes).10,11 Obesity is observed in 35%–60% 
of women with PCOS and is related to lack of or delayed 
response to different treatments such as clomiphene citrate 
(CC), gonadotropins, and surgical treatment of diathermy 
via laparoscopy.12
Weight loss improves the endocrine profile and increases 
the likelihood of ovulation and pregnancy. Normalization of 
the menstrual cycles and ovulation could occur with modest 
weight loss as little as 5% of the initial weight.13 Weight 
loss can improve not only circulating androgen and glucose 
levels but also ovulation and pregnancy rates in obese women 
with PCOS; however, weight loss is only recommended 
for those who are overweight with a BMI . 25–27 kg/m2. 
The treatment of obesity includes modifications in lifestyle 
(diet and exercise) and medical and surgical treatment. 
All these treatments must be performed during the precon-
ception period and not jointly with reproduction therapies.
Diet
Diets recommended for obese PCOS patients are low in calo-
ries with a reduced carbohydrate intake, and any form of these 
diets can produce the 5%–10% loss necessary to re-establish 
ovarian function in these patients. In 2005, Reaven suggested 
that low-fat diets produce a decrease in hyperinsulinemia, 
which improves metabolic effects.14
Exercise
Several studies have attempted to establish the role of exer-
cise in the treatment of obese PCOS patients.15 None found 
significant differences when different diets, associated or 
not with exercise, were compared, although a longer weight 
loss maintenance time did appear to be associated in these 
patients. An increase in physical activity is recommended 
for PCOS patients, although this often presents limitations.16 
A knowledge gap exists regarding the optimal type, duration, 
and frequency of exercise.
Bariatric surgery
Recently, bariatric surgery has been advocated as a strategy 
for weight loss in the morbidly obese. In addition, if sponta-
neous weight loss cannot be achieved with diet and exercise, 
bariatric surgery can be offered. Two primary approaches, 
restrictive and combined restrictive, and malabsorptive 
procedures, adjustable gastric banding, and the Roux-en-Y 
gastric bypass, are commonly performed. Not surprisingly, 
in 17 women with PCOS and a mean BMI of 50.7 kg/m2, 
bariatric surgery resulted in an average loss of 41 ± 9 kg in 
12 months and improvements in ovulation, insulin resistance, 
hyperandrogenism, and hirsutism.17 In a group of 12 PCOS 
patients available for follow-up after bariatric surgery for 
morbid obesity, regular cycles were restored in all.17 Of 
note, women who have had bariatric surgery are at increased 
risk for nutritional deficiencies, including protein, iron, 
vitamin B12, folate, vitamin D, and calcium; however, no 
consensus exists regarding optimal nutritional screening and 
supplementation.
Ovulation induction
In PCOS, anovulation relates to low FSH concentrations 
and the arrest of antral follicle growth in the final stages 
of maturation. Excess LH, androgens, and insulin may 
individually or collectively play a direct or indirect role 
in this process, augmenting steroidogenesis but arresting 
follicular growth. For many women, anovulatory infertility 
is the presenting complaint. Medications and other options 
available for the induction of ovulation are reviewed in the 
following sections.
CC
CC constitutes one of the first-line treatments for ovulation 
induction in these patients, as it is economical, is straightfor-
ward, has few adverse effects, and requires little monitoring.18 
CC is an estrogen receptor antagonist that interferes with 
negative feedback of the estrogen-signaling pathway, 
resulting in increased availability of FSH. Increased FSH 
leads to follicular growth, followed by an LH surge and 
ovulation. CC is indicated in patients with PCOS and anovu-
lation with normal FSH levels, but it has certain limitations 
in patients with a BMI . 30 and advanced age. Legro et al 
found significant differences in pregnancy rates in patients 
with a BMI . 30 compared with those with a BMI , 30.19
Doses of 50–150 mg are administered for 5 days, starting 
on days 3 or 5 of a progestin-induced or spontaneous cycle. 
CC produces ovulation in 75%–80% of PCOS patients, 
although when the gestation rate is assessed, it nears 22% 
per ovulation cycle.20 These differences in results are 
attributed to the antiestrogenic effects of CC, mainly on 
the endometrium and the cervical mucus.18 The live birth 
rate following 6 months of clomiphene ranged from 20% 
to 40%. Furthermore, the majority of pregnancies occurred 
within the first six ovulatory cycles following the initiation 
of treatment.19 Multiple pregnancy rates are under 10%, and 
hyperstimulation syndrome is rare. Tamoxifen is another International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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oral ovulatory agent that is similar to CC in its mechanism 
of action, but it lacks its antiestrogenic effect on the cervix 
and endometrium. It can be used as an alternative to CC in 
case of CC resistance or failure.
Metformin
Metformin is a biguanide currently used as an oral antihy-
perglycemic agent and is approved by the US Food and Drug 
Administration (FDA) to manage type 2 diabetes mellitus. 
The use of metformin is associated with increased menstrual 
cyclicity, improved ovulation, and a reduction in circulating 
androgen levels.21 Metabolic benefits are enhanced in the 
presence of weight loss, and weight loss itself may be 
enhanced in the presence of metformin. Its primary clinical 
action is to inhibit hepatic glucose production, although it 
also decreases intestinal glucose uptake and increases insulin 
sensitivity in peripheral tissues.22 Metformin likely plays its 
role in improving ovulation induction in women with PCOS 
through a variety of actions, including reducing insulin levels 
and altering the effect of insulin on ovarian androgen bio-
synthesis, theca cell proliferation, and endometrial growth. 
In addition, potentially through a direct effect, it inhibits 
ovarian gluconeogenesis and thus reduces ovarian androgen 
production.
Several dose regimens have been proposed.23 In order to 
increase patient tolerance, metformin is started at 500 mg daily 
with food. After 1 week, the dose is increased to 1000 mg 
for another week and then to 1500 mg daily. The target dose 
is 1500–2550 mg/day (500 or 850 mg three times daily). 
Clinical response is usually seen at the dose of 1000 mg daily. 
It appears that some PCOS patients who do not respond to 
metformin at a dose of 1500 mg daily will respond favorably 
to 2000 mg daily. The most common side effects of metformin 
are nausea and diarrhea. Lactic acidosis has been described 
mainly in patients with renal impairment, congestive heart 
failure, and sepsis. Traditionally, oral hypoglycemic agents 
have been regarded as teratogenic, and their use is contrain-
dicated in pregnancy. However, an increasing amount of data 
supports their safety when used throughout the pregnancy. 
Glueck et al reported no major birth defects and no effect on 
motor or social development of infants at 3 and 6 months 
of age.24 Compared with the control group of women who did 
not receive metformin, the incidence of gestational diabetes 
in the treated group was significantly lower.
To define the exact role of metformin in ovulation induc-
tion, it is crucial to distinguish two different indications. In 
naive PCOS, metformin, as compared with placebo, has been 
shown to improve ovulation rates, but metformin did not exert 
significant advantage over CC with respect to cumulative 
ovulation, pregnancy, or live birth rates.25 The combined 
approach of metformin plus CC is not better than CC or 
metformin monotherapy in naive PCOS.26 In CC-resistant 
patients, metformin has no benefit over placebo in ovula-
tion, pregnancy, and live birth rates as a single agent, but the 
combination of metformin and CC significantly improved 
ovulation and pregnancy rates when compared with CC 
alone. However, combined therapy did not improve the odds 
of live birth.27 Metformin pretreatment improves the efficacy 
of CC in PCOS patients with CC resistance.28
Troglitazone is another insulin-sensitizing drug that has 
been shown to improve ovulation and increase pregnancy 
rates. However, due to its hepatotoxic effect, it has been 
withdrawn from the market.29 Another drug in the same 
category, rosiglitazone (8 mg/day), has been shown to 
enhance both spontaneous and clomiphene-induced ovulation 
in women with PCOS with a mean BMI of 35.5–38.5 kg/m2. 
Pioglitazone appears to be effective as well; however, 
the study is still limited. Although both rosiglitazone and 
pioglitazone have little short-term risk, fetal safety has not 
been established (pregnancy category C of the US FDA 
guidelines). If used, they should be discontinued as soon 
as pregnancy has been established. Recently, Tang et al 
updated the Cochrane review about insulin-sensitizing drugs 
(metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for 
women with PCOS, oligo/amenorrhea, and subfertility and 
concluded that metformin is still of benefit in improving 
clinical pregnancy and ovulation rates. However, there is no 
evidence that metformin improves live birth rates whether 
it is used alone or in combination with clomiphene, or when 
compared with clomiphene. Therefore, the use of metformin 
in improving reproductive outcomes in women with PCOS 
appears to be limited.30
Aromatase inhibitors
Selective aromatase inhibitors such as anastrozole and 
  letrozole are promising new ovulation-inducing agents. They 
are reversible and highly potent. Unlike CC, which has a 
half-life of 5–7 days, the mean half-life of anastrozole and 
letrozole is ∼45 h only. To date, letrozole has been studied 
much more extensively than anastrozole.31 Letrozole was 
introduced as an assisted reproduction treatment follow-
ing the appearance of multiple adverse effects of CC, CC’s 
scant therapeutic success, and the complexity of gonado-
tropin treatment. Letrozole inhibits estrogen production in 
the hypothalamus–pituitary axis, which implies an increase 
in gonadotropin-releasing hormone (GnRH) and FSH. It is International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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believed that there exists a relative decrease in aromatase 
in women with PCOS, which reduces the production of 
follicles responsible for efficacious ovulation. To use this 
relative deficit, aromatase inhibitors were considered in 
order to provoke ovulation, because their selective action of 
blocking the peripheral passage of androgens to estrogens 
reduces the quantity of   estrogens, thereby producing positive 
feedback in the pituitary, increasing FSH, and optimizing 
ovulation. The advantage of letrozole is that it avoids 
peripheral antiestrogenic effects on the endometrium while 
stimulating monofollicular growth.32 Letrozole at 2.5–5 mg 
is administered for 5 days and may be accompanied by FSH 
(at the normal doses for PCOS patients) and human chorionic 
gonadotropin (hCG; 10,000 IU) when the follicle diameter 
reaches 18 mm in order to program the ovulation. However, 
in a prospective randomized trial comparing letrozole with 
clomiphene, pregnancy rates were similar. Although Novartis 
Pharmaceuticals (Basel,   Switzerland) has warned against the 
use of letrozole for ovulation induction (owing to possible 
teratogenicity), a comparison with   clomiphene did not dem-
onstrate increased rates of major or minor malformations.33
Glucocorticoids
Glucocorticoids such as prednisone and dexamethasone have 
been used to induce ovulation. Elnashar et al demonstrated 
that induction of ovulation by adding dexamethasone (high 
dose, short course) to CC in CC-resistant PCOS with normal 
DHEAS is associated with no adverse antiestrogenic effect 
on the endometrium and higher ovulation and pregnancy 
rates in a significant number of patients.34
In PCOS patients with high adrenal androgen, low-dose 
dexamethasone (0.25–0.5 mg) at bedtime can be used.35 In a 
study of 230 women with PCOS who failed to ovulate with 
200 mg of CC for 5 days, addition of 2 mg of dexametha-
sone from days 5–14 is associated with a higher ovulation 
rate and cumulative pregnancy rate.36 Enthusiasm for their 
use is dampened, however, by their potential adverse effects 
on insulin sensitivity; therefore, prolonged use should be 
discouraged.
Gonadotropins
The second possible line of therapy after resistance to CC 
has been demonstrated in women with PCOS is exogenous 
gonadotropins.37 The mechanism of action of gonadotropins 
is to induce ovulation, maintain and provoke optimum follicle 
growth via the controlled administration of FSH, and achieve 
a follicle capable of being fertilized. Unlike CC, gonadotropin 
does not exert a peripheral antiestrogenic effect. The main 
drawback of gonadotropins is that they provoke multiple 
follicle development, thereby increasing the risk of ovarian 
hyperstimulation syndrome (OHSS) and multiple   pregnancies. 
Treatment with FSH is expensive, is time consuming, and 
requires expertise and stringent monitoring. OHSS is related 
to hCG-mediated production of vasoactive mediators after 
gonadotropin-induced multifollicular development.38
Several treatment protocols have been advocated, such 
as step-up, low-dose step-up, and step-down regimens. The 
ASRM recommends low-dose gonadotropin protocols.39 
A step-up dose-finding approach favoring unifollicular devel-
opment is recommended. The step-up regimen starts with a 
minimum dose (37.5–50 IU/day), which increases according 
to the lack of follicle response. Control is made by ultrasound, 
and the regimen is modified after 1 week of no follicle growth 
with a 50% increase each time as required. HCG is used as 
a surrogate for the LH surge, leading to maturation of the 
oocyte, rupture of the follicle, and formation of the corpus 
luteum. The step-down regimen starts with the maximum 
recommended dose, which is reduced as a follicle response 
is achieved. The dose is reduced by 50% each time the regi-
men is changed. Recent studies have demonstrated greater 
safety for patients using the step-up regimen.40
In 2006, the ASRM advocated caution and strict 
control when blood estradiol levels exceed 2500 pg/mL 
during induction.39 Current recommendations suggest 
withholding hCG administration in the presence of more than 
two follicles .16 mm or more than one follicle .16 mm 
and two additional follicles .14 mm, or if serum estradiol 
levels are between 1000 and 2500 pg/mL, particularly in 
women ,38 years old without any other infertility factors. 
Overall, low-dose regimens resulted in a monofollicular 
ovulation rate of ∼70%, a pregnancy rate of 20% per cycle, 
and a multiple live birth rate of 5.7% while maintaining a low 
incidence of multiple pregnancies (,6%) and OHSS (,1%).41 
A maximum of six cycles with gonadotropins is recommended 
because no response with six cycles signifies resistance.
Laparoscopic ovarian diathermy
In clomiphene-resistant PCOS women who are unable to 
comply with the close monitoring necessary for gonadotropin 
administration, bilateral laparoscopic ovarian surgery with 
monopolar electrocautery (multiple controlled perforation 
of the ovary) or laser is an acceptable alternative; both 
modalities confer similar results.42 Laparoscopic ovarian 
diathermy (LOD) is associated with lower multiple ges-
tation rates than gonadotropins. In a Cochrane Database 
Systematic Review article, there was no evidence of a International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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difference in live birth rate and miscarriage rate in women 
with clomiphene-resistant PCOS undergoing LOD versus 
gonadotropin treatment. It appears to be more effective in 
patients with high LH, and significant reductions in LH 
and androgens have been shown following surgery. LOD 
restores menstrual regularity in 63%–85% of women, and the 
beneficial effects on reproductive outcomes seem to last for 
several years in many women.43 Treatment with metformin 
is equally efficacious in correcting the clinical, endocrine, 
and metabolic abnormalities associated with PCOS.44
In vitro fertilization techniques
The last possibility for achieving a full-term pregnancy 
in women with PCOS is to use in vitro fertilization (IVF) 
techniques.6 Patients with PCOS are characterized by ano-
vulatory cycles that conceptually are not an indication for 
IVF techniques. These techniques are used as a last resort 
when treatments with CC, gonadotropins, and letrozole 
have failed. IVF is the first choice in cases of concomi-
tant diseases both in women (severe endometriosis, tubal 
o  bstruction, etc) and men (azoospermia, male factor) that 
reduce the   effectiveness of other techniques. Because of 
the increased risk of multiple gestations (up to 10%) with 
gonadotropin induction in a  novulatory women with PCOS, 
IVF is a reasonable alternative for women seeking pregnancy. 
IVF with a single embryo transfer significantly reduced the 
risk of multiple gestation.45 IVF allows the placement of 
only one embryo or for cryopreservation of all embryos, 
with transfer of a single embryo in a subsequent cycle with 
endometrial but not ovarian stimulation IVF.
Several stimulation protocols have been published for 
the treatment of patients with PCOS undergoing IVF, includ-
ing combinations or isolated use of clomiphene, human 
menopausal gonadotropins, recombinant FSH, GnRH 
agonists, and GnRH antagonists.46,47 According to the 
2008 ASRM consensus conference, the most commonly 
employed protocol is a long FSH desensitization protocol in 
which an agonist is started in the early, mid-, or late luteal 
phase in the preceding cycle or in the follicular phase until 
hCG administration. Stimulation with gonadotropins is started 
when pituitary and ovarian suppression has been achieved.48 
A meta-analysis published in 2006, which studied the results 
of conventional IVF techniques in women with PCOS, 
revealed more cycle cancellation and that the duration of 
stimulation cycles was significantly longer in women with 
PCOS.49 There is evidence that the use of metformin improves 
viable pregnancy rates and reduces the incidence of OHSS.50 
The success of IVF techniques is similar to that of patients 
without PCOS, which implies that PCOS does not intervene 
in embryo implantation.
Treatment of menstrual dysfunction
Chronic anovulation is associated with an increased risk of 
endometrial hyperplasia and carcinoma.51 Thus, it is prudent 
to consider endometrial biopsy in patients with PCOS who 
have not had menstrual bleeding for a year or longer. Some 
investigators have advocated the use of ultrasonography to 
determine endometrial thickness in deciding whether to do 
a biopsy of the endometrium. Endometrial proliferation can 
be inhibited by administering either cyclic progestin or oral 
contraceptives with a combination of estrogen and progestin. 
The latter approach, which also reduces ovarian androgen 
production, may be particularly beneficial in this setting.
Treatment of androgen-related symptoms
The over-riding androgenic symptoms that the individual 
presents will vary from patient to patient; for some it is 
mainly hirsutism, but for others it is acne and/or alopecia. 
Many have both hirsutism and acne, and a few complain of 
significant acne, hirsutism, and alopecia.52
Hirsutism
Overall, 70%–80% of women with excess androgen dem-
onstrate hirsutism, usually defined as a Ferriman–Gallwey 
score of at least 8, although this prevalence is less in certain 
ethnic groups, such as East Asians, who may have fewer hair 
follicles endowed per unit area of skin.53 Androgens increase 
the growth rate of hair and transform vellus hair to terminal 
hair. Reduction of androgens reduces new hair growth and 
slows the growth of terminal hair that is already present.54 Hair 
grows in nonsynchronous cycles. The growth or anagen phase 
varies according to body area and is ∼4 months for facial hair. 
Given this long hair growth cycle, the effects of hormonal 
therapy require more than 6 months to be maximal.
Oral contraceptive pills
In women who have no desire to conceive, they can be 
treated with oral contraceptive pills (OCPs). OCPs reduce 
hyperandrogenism by promoting direct negative feedback on 
LH secretion, which results in decreased ovarian synthesis 
of androgens. Further, they increase liver production of sex 
hormone-binding globulin and subsequently decrease circu-
lating free androgen. Other mechanisms include reduction 
in adrenal androgen secretion and inhibition of peripheral 
conversion of testosterone to dihydrotestosterone and binding 
of dihydrotestosterone to androgen receptors.55 The choice International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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of oral contraceptive is important, because most progestins 
also possess variable androgenic effects. Available low-dose 
OCPs (defined as ,50 µg) contain ethinyl estradiol in doses 
ranging from 15 µg to 35 µg. An important consideration for 
the progestin component is the degree of androgenicity of the 
progestin.56 Newer OCPs contain fewer androgenic progestins 
(such as norethindrone, desogestrel, and norgestimate), and 
two progestins (cyproterone acetate [CPA], which is used in 
low doses in OCPs, and drospirenone) function as androgen 
receptor antagonists, CPA being more potent in its effect. 
CPA may also inhibit 5-α-reductase activity, decreasing 
the availability of the more potent androgen, dihydrotestos-
terone.57 A third antiandrogenic progestin, dienogest, has 
recently become available in Europe and is combined with 
estradiol as an OCP. One of the newest OCPs that might be 
more effective in reducing the growth of new terminal hair 
and acne formation is a formula that contains a combina-
tion of nonandrogenic progestin, drospirenone, and ethinyl 
  estradiol; thus, it is potentially ideal for the treatment of 
women with PCOS. Drospirenone is a spironolactone analog 
with mineralocorticoid activity; as a result, it has some diuretic 
property. However, it should not be prescribed to those predis-
posed to hyperkalemia. Treatment must be given for at least 
6–9 months before improvement in hirsutism can be seen.56
Estrogen–progestin combination therapy (with the use 
of a combination OCP) remains the predominant treatment 
for hirsutism and acne in PCOS.4 Controversy persists 
regarding the use of OCPs as first-line therapy in women 
with PCOS. These agents clearly improve hirsutism and acne 
and protect against unopposed estrogenic stimulation of the 
endometrium, but their potential adverse effects on insulin 
resistance, glucose tolerance, vascular reactivity, and coagu-
lability are a concern, particularly now that insulin-lowering 
agents are available.
Antiandrogens
Antiandrogens such as spironolactone, CPA, or flutamide 
act by competitive inhibition of androgen-binding receptors 
or by decreasing androgen production.58
Spironolactone, which is an aldosterone antagonist, is 
a dose-dependent competitive inhibitor of the androgen 
receptor and can also inhibit 5-α-reductase activity. 
Spironolactone possesses moderate antiandrogenic effects 
when administered in large doses (100–200 mg daily). It has 
demonstrable effects on hirsutism over and above those 
induced by OCPs.59 Although generally well tolerated, it 
occasionally causes fatigue, postural hypotension, and diz-
ziness, and when administered alone in high doses, it may 
cause menstrual irregularity. The risk of feminizing a male 
fetus, if pregnancy occurs, precludes its use as monotherapy 
in sexually active women with PCOS. Spironolactone and 
oral contraceptives appear to be synergistic.60 Thus, it is often 
used with OCPs.
CPA is a progestational antiandrogen. CPA competitively 
inhibits the binding of testosterone and its more potent 
conversion product 5a-dihydrotestosterone to the andro-
gen receptor. Used in high doses (50–100 mg) and in a 
reverse sequential regimen (for the first 10 days of cycle), 
in combination with ethinyl estradiol 20–50 µg (to ensure 
regular menses), it was shown to be more effective than 
finasteride, a 5-α-reductase inhibitor.61 CPA is generally 
well tolerated, although it may cause headaches, nausea, 
weight gain, breast tenderness, loss of libido, and, rarely, 
hepatotoxicity effects. As with spironolactone, there is a 
risk of feminizing a male fetus. A combination of ethinyl 
estradiol and CPA is very effective in treating hirsutism and 
acne. Apart from its antiandrogenic effect, CPA has a marked 
progestational property preventing ovulation.62 Loss of hair, 
which frequently accompanies seborrhea, also improves. 
Frequent monitoring of liver and renal function is necessary 
during therapy with antiandrogens. Similar to that with OCP, 
improvement of hirsutism is expected to be noticeable after 
6 months of treatment. Although there is a considerable 
variation among individuals, the maximum effect is usually 
seen after 9–12 months of antiandrogen treatment.
Flutamide is a nonsteroidal, selective antiandrogen with-
out progestogenic effect. It is marketed for the treatment of 
prostate cancer and is very effective in treating hirsutism. In a 
dose of 500 mg daily, it was found to be similarly effective as 
spironolactone 100 mg in women with idiopathic hirsutism, 
and, in a recent study, the minimal effective dose was found to 
be 125 mg daily. Its major concern is serious hepatotoxicity, 
although doses up to 375 mg have been used without any 
significant hepatotoxicity.63 However, it is rarely used alone 
due to its high cost and the risk of hepatocellular toxicity. 
Recent studies have indicated that a combination of flutamide 
62.5 mg daily with metformin 850 mg daily is more effective 
in improving symptoms of PCOS than OCP alone.64
Finasteride is a type 2 (5-α-reductase) activity inhibitor 
that inhibits the production of dihydrotestosterone. Enhanced 
5-α-reductase activity in hirsutism probably involves both 
type 1 and type 2 enzymes, so it is unlikely to be an optimal 
treatment. Hirsutism scores were lower in studies of finas-
teride.65 Comparison of finasteride with spironolactone has 
shown equal or lesser efficacy of finasteride. Finasteride has 
also been used in combination with a CPA-containing OCP, International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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and the addition of finasteride 5 mg to the OCP was shown 
to be better than the OCP alone.66 When finasteride was 
compared directly with an OCP-containing low-dose CPA, 
the effect was equivalent. Although finasteride has a low side 
effect profile, its feminizing effects on a male fetus preclude 
its use in most patients. Due to the risk of feminization of 
a male fetus, pregnancy must be avoided during treatment 
with all antiandrogens.67
Glucocorticoids
Some women with PCOS have elevated adrenal androgen 
levels, although their contribution to ovulatory dysfunction 
appears modest.68 Glucocorticoids suppress adrenal andro-
gen secretion and have been used in patients with adrenal 
hyperandrogenism. Their use is most legitimate in patients 
with classic congenital adrenal hyperplasia, where they can 
help prevent and manage hirsutism and allow ovulatory 
cycles. In nonclassic congenital adrenal hyperplasia and 
functional adrenal androgen excess (a minority of PCOS 
patients), their role is more limited.69 Suppression of adre-
nal androgens results in a minor improvement of hirsutism, 
although prolonged remission after therapy withdrawal can 
be obtained. A trial of CPA versus hydrocortisone in patients 
with late-onset congenital adrenal hyperplasia showed a 
greater decrease in hirsutism scores with 1 year of CPA 
compared with hydrocortisone (54% vs 26%). These results 
occurred despite a greater reduction of androgens with 
glucocorticoids, highlighting the importance of peripheral 
receptivity to androgens.70 Overdosing can occur, leading 
to adrenal atrophy, weight gain, and decreased bone mineral 
density. Glucocorticoid (5–7.5 mg of prednisone once or 
twice daily) has been shown to improve hirsutism in women 
with congenital adrenal hyperplasia. However, its effect on 
hirsutism due to other causes is unclear.65 Unless a woman 
with PCOS has marked adrenal androgen excess, prolonged 
use of glucocorticoids is not advised.
Gonadotropin-releasing hormone agonist
Gonadotropin-releasing hormone agonist (GnRHa) is 
  effective even in women with severe insulin resistance who 
are unresponsive to OCP.71 GnRHa suppresses pituitary 
hormones, decreases androgen and estradiol secretion, and 
improves severe forms of hirsutism. To avoid problems 
associated with estrogen deficiency, ‘add-back’ therapy 
with estrogen–progesterone or low-dose OCP is advisable. 
However, this method of treatment is expensive, limiting 
its use to severe forms of ovarian hyperandrogenism with 
hyperinsulinemia.
Insulin-lowering agents
Both metformin and thiazolidinediones may lower ovarian 
androgen secretion, mainly through their insulin-lowering 
effects. In a Cochrane Databse Systematic Review article, 
limited data on small numbers of patients have shown no evi-
dence of a difference in effect between metformin and OCPs on 
hirsutism and acne.72 Some effects of rosiglitazone on hirsutism 
were shown by Yilmaz et al and troglitazone (no longer avail-
able) improved hirsutism in women with PCOS.72
Direct hair removal
Electrolysis has been used for many years to remove 
unwanted hair. A fine needle is inserted into the hair fol-
licle, and an electrical current is applied. Erythema and 
postinflammatory pigment changes may occur, and scarring 
is possible.73 Photoepilation uses laser and nonlaser light 
sources to damage hair follicles, but vellus hair remains and 
can be converted to terminal hair. Although laser treatment 
is more expensive, it is less painful and much faster.74 There 
is potential for depigmentation and scarring with laser use, 
especially in darker-skinned women.
Topical treatment
Eflornithine hydrochloride, an inhibitor of the enzyme ornithine 
decarboxylase in human skin, has been approved for topical 
use in treating facial hirsutism, taking 6–8 weeks for its effect 
to be apparent.75 It can be combined with laser treatment.
Combination therapy
In the Endocrine Society Practice Guidelines discussing 
the evaluation and treatment of hirsutism in premenopausal 
women, it was recommended that OCPs or direct hair 
removal be used initially.76 Then, if at least 6 months of 
OCP therapy has not significantly decreased the rate of hair 
growth, antiandrogens may be added.
Acne
Both OCPs and antiandrogens have been used successfully in 
the treatment of acne.77 Within 3–6 months of OCP treatment, 
inflammatory acne counts are reduced by 30%–60%, with 
improvement in 50%–90% of patients. OCPs are especially 
useful in patients with deep-seated nodules and helpful in 
patients relapsing on isotretinoin.
Alopecia
There are no extensive trials for alopecia, but OCPs and 
androgen blockers are usually administered. In limited 
s  tudies, CPA has had some effect, as has finasteride.78International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Alternative medicine and PCOS
Absence of evidence is not evidence of absence. Alternative 
medicine has been emerging as one of the commonly 
practiced medicines for different health problems.   Alternative 
medicines include many modalities, such as kinesiology, 
herbalism, homeopathy, reflexology, acupressure, acu-
puncture, and massage therapy. Acupuncture is the most 
common modality. The benefit acupuncture seems to have 
for PCOS sufferers is in helping them regulate and manage 
their periods. However, it has also been shown to aid in 
weight loss and reducing headaches as well as improving 
patients’ moods and outlooks. Women with PCOS will have 
needles placed along the acupuncture meridians related to 
the reproductive system. This will help stimulate the organs, 
improve blood flow to the area, contribute to normalizing 
hormone levels, and promote the proper functioning of the 
reproductive system.
Because it is only in the last 20 years or so that acu-
puncture has started to be widely practiced in the West, few 
studies have been performed on women with PCOS receiving 
acupuncture. In 2000, a study was carried out by researchers 
at Göteborg University in Sweden involving 24 women with 
PCOS who received acupuncture for 2–3 months. At the 
end of the study, nine women (38%) had regular ovulation. 
However, the study also found that those women with more 
severe PCOS cases, particularly those participants who had 
high testosterone and insulin levels and were obese, did not 
have any luck with the acupuncture treatment.79 Recently, 
a randomized controlled trial proved the efficacy of electroa-
cupuncture in treating women with PCOS.80
In conclusion, it is clear that PCOS is an enigma. Its under-
lying pathophysiology is not fully understood. No treatment 
is a panacea, because treatments, so far, have been directed at 
the symptoms but not at the syndrome itself. Extensive efforts 
should be made to fully investigate the syndrome in order to 
make therapy more successful and to delay the serious long-
term effects of the disease on patients’ health.
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